News | March 02, 2009

Breast-Specific Gamma Imaging Uncovers Additional Breast Cancer in Newly Diagnosed Patients

March 2, 2009 - Women facing a recent breast cancer diagnosis may find additional cancer in the same or opposite breast with further testing using Breast-Specific Gamma Imaging (BSGI) according to a study published in the February 2009 "American Journal of Surgery."

BSGI detected additional or more extensive breast cancer in the same or opposite breast in 10.9 percent of newly diagnosed patients according to the study.

BSGI, a molecular breast imaging technique, is a follow-up to mammography that can see lesions independent of tissue density and discover early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on the BSGI image. The Dilon 6800 Gamma Camera is a high-resolution, compact field-of-view gamma camera, optimized to perform BSGI.

"The research is important because it helps clarify the role of BSGI in newly diagnosed breast cancer patients,” said Nathalie Johnson, M.D., general surgeon and surgical oncologist at Good Samaritan Hospital, Portland, OR. “We have found that these women can have more extensive disease that is not detected by mammography or ultrasonography. This is especially helpful in patients with dense breast tissue where additional evaluation of the remaining breast tissue is necessary."

Dr. Johnson and her team conducted a retrospective review from two Portland community-based breast imaging centers of newly diagnosed breast cancer patients in whom BSGI was performed as part of the imaging work-up. BSGI detected additional or more extensive malignancy in the same or opposite breast in 10.9 percent of newly diagnosed breast cancer patients. Only 7.2 percent incurred an additional work-up. The study concluded that BSGI provides accurate evaluation of remaining breast tissue in newly diagnosed breast cancer patients with few false-positive readings.

BSGI has comparable sensitivity, but superior specificity when compared to magnetic resonance imaging (MRI), which leads to improved management of the newly diagnosed breast cancer patient. Sensitivity refers to the ability of an imaging technique to detect the presence of disease. Specificity refers to the technique's ability to detect that disease is actually not present.

"The biggest benefit of BSGI is the specificity. The sensitivity of BSGI is on par with MRI, but the specificity is higher than MRI. In addition, when compared to MRI, BSGI is less expensive and easier to use for patient and physician," said Dr. Johnson.

A total of 138 patients (69 invasive ductal carcinoma, 20 invasive lobular carcinoma, 32 ductal carcinoma in situ, and 17 mixtures of invasive ductal carcinoma, invasive lobular carcinoma, or ductal carcinoma in situ and other) were reviewed. Twenty-five patients (18.1 percent) had a positive BSGI study for cancer at a site other than their known cancer, or more extensive disease than was detected from previous imaging. Fifteen patients (10.9 percent) were positive for a synchronous or more extensive cancer in the same or opposite breast. Five patients had benign findings on pathology, five benign on ultrasound follow-up (false-positive rate, 7.2 percent). Findings converted seven patients to mastectomy, one patient to neoadjuvant chemotherapy, and seven patients were found to have previously undetected contralateral cancer. The positive predictive value for BSGI was 92.9 percent.

The full study can be found in “The American Journal of Surgery” (Vol. 197, No 2, February 2009).

For more information: www.dilon.com

Related Content

The ASPIRE Cristalle FFDM system with DBT combines Fujifilm’s state-of-the-art hexagonal close pattern (HCP) detector design, advanced image processing and image acquisition workflow
News | Women's Health | August 01, 2017
Fujifilm Medical Systems U.S.A., Inc. announced that The Mammography Center of Monterey, an ACR-accredited breast...
Sponsored Content | Videos | Breast Imaging | July 28, 2017
Nancy Cappello, Ph.D., executive director and founder of Are You Dense Inc. and Are You Dense Advocacy, explains how
X-ray performed on a GE Optima 646 DR system. The FDA has updated its radiology reporting forms on its website.
News | Business | July 24, 2017
July 24, 2017 — The U.S.
Kubtec Launches New Website For Digital Imaging and Irradiation Products
News | Digital Radiography (DR) | July 20, 2017
Kubtec announced the launch a new website focused on the applications of digital X-ray imaging and irradiation for...
Volpara Solutions to Showcase Volpara Enterprise DDP Software at AHRA 2017
News | Mammography | July 11, 2017
Volpara Solutions Inc. will showcase its new Volpara Enterprise DDP software at the Association for Medical Imaging...
Fujifilm Showcases Digital Radiography, Mammography Innovations at AHRA 2017
News | Digital Radiography (DR) | July 06, 2017
Fujifilm Medical Systems U.S.A. Inc. will present its comprehensive portfolio of digital radiography (DR) and...
Feature | Breast Density | July 05, 2017 | By Nancy M. Cappello, Ph.D.
Two decades of research on the masking risk of dense breast tissue by mammography screening is indisputable. As the...
Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50
News | Mammography | June 30, 2017
June 30, 2017 — Solis Mammography was named the 19th fastest-growing, middle-market company in North Texas by the
GE Healthcare Announces First U.S. Installation of Senographe Pristina Mammography System
News | Mammography | June 29, 2017
GE Healthcare has collaborated with Boca Raton Regional Hospital (Boca Raton, Fla.) to bring a more comfortable...
New Study Highlights Breakthrough Therapy to Reduce Mammographic Breast Density
News | Breast Density | June 28, 2017
Stephen N. Birrell, M.D., Ph.D., presented breakthrough findings into the reduction of mammographic breast density at...
Overlay Init